

Chemours Co  
Form 4  
July 06, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Vanlancker Thierry FJ

(Last) (First) (Middle)  
1007 MARKET STREET  
(Street)

WILMINGTON, DE 19899

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Chemours Co [CC]

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/01/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)

President - Fluoroproducts

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |
| Common Stock, par value \$.01   | 07/01/2015                           |  | A                              |   | 138,019 (1)   | A  | \$ 0                              |
|                                 |                                      |  |                                |   | 140,972 (2)   | D  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: Chemours Co - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (Right to Buy)                | \$ 11.8693   | 07/01/2015                           |  | A <sup>(3)</sup>               | 32,678  | <sup>(4)</sup> 02/05/2020                                | Common Stock  | 32,678                        |
| Stock Option (Right to Buy)                | \$ 15.4871   | 07/01/2015                           |  | A <sup>(3)</sup>               | 25,568  | <sup>(5)</sup> 02/04/2021                                | Common Stock  | 25,568                        |
| Stock Option (Right to Buy)                | \$ 18.4494   | 07/01/2015                           |  | A <sup>(3)</sup>               | 30,152  | <sup>(6)</sup> 02/03/2022                                | Common Stock  | 30,152                        |

## Reporting Owners

| Reporting Owner Name / Address                                      | Relationships |           |                            |       |
|---|---------------|-----------|----------------------------|-------|
|   | Director      | 10% Owner | Officer                    | Other |
| Vanlancker Thierry FJ<br>1007 MARKET STREET<br>WILMINGTON, DE 19899 |               |           | President - Fluoroproducts |       |

## Signatures

/s/ Brian Morrissey, as attorney-in-fact for Thierry F.J. Vanlancker 07/06/2015

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted stock units granted in accordance with the Employee Matters Agreement (the "Agreement") dated as of June 26, 2015 between the Issuer and E. I. du Pont de Nemours and Company ("DuPont") to replace restricted stock units and related dividend equivalent units of DuPont held by the Reporting Person immediately before the legal and structural separation of Issuer from DuPont (the "Spin-off").
- (2) Includes shares of Issuer common stock received in connection with the Spin-off in an exempt transaction pursuant to Rule 16a-9 based on preliminary information regarding the Spin-off. Final amounts, if different, will be reported in a subsequent filing.
- (3)

## Edgar Filing: Chemours Co - Form 4

Award replaces stock options of DuPont held by the Reporting Person immediately before the Spin-off pursuant to the Agreement. Information reported in this row is estimated as of July 6, 2015 based on preliminary information regarding the Spinoff. Final information, if different, will be reported in a subsequent filing.

- (4) Includes 21,785 options to purchase shares of Issuer common stock that are immediately exercisable. The remaining options vest on February 6, 2016.
- (5) Includes 8,523 options to purchase shares of Issuer common stock that are immediately exercisable. The remaining options vest in two approximately equal annual installments beginning February 5, 2016.
- (6) Options to purchase shares of Issuer common stock vest in three approximately equal annual installments beginning February 4, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.